Terms ending in 2039
Every in-force patent on Astellas Pharma Inc.'s record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,679,166 | Novel Anti-Human MUC1 Antibody Fab Fragment In force · Low confidence | Astellas Pharma Inc. | In force | Low confidence | |
| US 11,787,862 | Bispecific Trivalent Antibodies Binding to CLAUDIN6 or CLAUDIN18.2 and CD3 for Treatment of Claudin Expressing Cancer Diseases In force · High confidence | BioNTech SE | In force | High confidence | |
| US 11,638,730 | Cancer Therapy by Combination Use of Oncolytic Vaccinia Virus and Immune Checkpoint Inhibitor, and Pharmaceutical Composition and Combination Medicine for Use in the Cancer Therapy In force · High confidence | Astellas Pharma Inc. | In force | High confidence | |
| US 11,473,071 | Method for Treating Muscular Dystrophy by Targeting Utrophin Gene In force · High confidence | Modalis Therapeutics Corporation | In force | High confidence | |
| US 11,578,067 | Novel Compound, And Method For Producing Regulatory T Cells In force · High confidence | Kyoto University | In force | High confidence | |
| US 11,667,724 | Novel Anti-Human CEACAM5 Antibody Fab Fragment In force · High confidence | Astellas Pharma Inc. | In force | High confidence |
6 of 6 patents shown. Soonest term end first, then patent number.
3 of these are in force and held by Astellas Pharma Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.